CD19 chimeric antigen receptor-modified T cell therapy - Wuhan Sian Medical Technology

Drug Profile

CD19 chimeric antigen receptor-modified T cell therapy - Wuhan Sian Medical Technology

Alternative Names: CD19-CAR T cell therapy - Wuhan Sian Medical Technology

Latest Information Update: 22 Nov 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Sian Wuhan Medical Technology
  • Developer Sian Wuhan Medical Technology; Wuhan Union Hospital
  • Class Antineoplastics; CAR-T cell therapies
  • Mechanism of Action T-cell receptor antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Acute lymphoblastic leukaemia

Most Recent Events

  • 01 Apr 2016 Phase-I clinical trials in Acute lymphoblastic leukaemia (Second-line therapy or greater, Refractory metastatic disease) in China (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top